Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Operations (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Cash from Operations for 2 consecutive years, with 17287000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 37.09% to 17287000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 62271000.0 through Dec 2025, up 7.94% year-over-year, with the annual reading at 62271000.0 for FY2025, 7.94% up from the prior year.
  • Cash from Operations hit 17287000.0 in Q4 2025 for Silence Therapeutics, down from 10884000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 5409000.0 in Q2 2024 to a low of 27481000.0 in Q4 2024.